Company profile
Cyclerion Therapeutics, Inc.
NASDAQ:CYCNBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| OLINCIGUAT | phase2 | — | 3 | no active trials |
| PRALICIGUAT | phase2 | — | 6 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02906579 | phase2 | completed | 2016-09-01 | 2017-03-17 | Cyclerion Therapeutics | A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension |
| NCT03285178 | phase2 | completed | 2017-12-22 | 2020-07-22 | Cyclerion Therapeutics | A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD) |
| NCT02792998 | phase1 | completed | 2016-05-01 | 2016-11-01 | Cyclerion Therapeutics | A Trial of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Healthy Subjects |
| NCT03499106 | phase1 | completed | 2018-04-12 | 2018-07-06 | Cyclerion Therapeutics | A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of Praliciguat (IW-1973) in Healthy Volunteers |
| NCT03892499 | phase1 | completed | 2019-05-03 | 2019-06-23 | Cyclerion Therapeutics | A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator, Olinciguat (IW-1701), in Healthy Volunteers |
FDA applications (0)
No records yet.